Form 4 for KNSA Kiniksa Pharmaceuticals International, plc
Accepted 2026-05-05 16:54:33 ET · period of report 2026-05-01 · accession 0001741533-26-000008 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-05-05 16:54 | 2026-05-01 | KNSA | Paolini John F. | Chief MEDICAL Off | M - OptEx | $10.36 | +58.4K | 124.0K | +89% | +$605.3K |
| DMT | 2026-05-05 16:54 | 2026-05-01 | KNSA | Paolini John F. | Chief MEDICAL Off | S - Sale+OE | $53.71 | -58.4K | 65.6K | -47% | -$3.14M |
| DT | 2026-05-05 16:54 | 2026-05-01 | KNSA | Paolini John F. | Chief MEDICAL Off | M - OptEx | $0.00 | -58.4K | 29.7K | -66% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Ordinary Share | 2026-05-01 | M | A | 58,424 | $10.36 | 124,047 | D | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on November 18, 2025. |
| 2 | Common | Class A Ordinary Share | 2026-05-01 | S | D | 37,327 | $53.52 | 86,720 | D | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on November 18, 2025. (F2) This transaction was executed in multiple trades through a broker-dealer at prices ranging between $52.765 and $53.76. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. |
| 3 | Common | Class A Ordinary Share | 2026-05-01 | S | D | 21,097 | $54.04 | 65,623 | D | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on November 18, 2025. (F3) This transaction was executed in multiple trades through a broker-dealer at prices ranging between $53.765 and $54.22. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. |
| 4 | Derivative | Share Option | 2026-05-01 | M | D | 58,424 | $0.00 | 29,670 | D | $10.36 · — to 2028-02-29 | 58,424 Class A Ordinary Share | (F1) This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on November 18, 2025. (F4) The option is fully vested and exercisable. |